← Back to Screener
Minerva Neurosciences, Inc (NERV)
Price$4.96
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)10.74%
Price vs S&P 500 (4W)-15.64%
VGM Score67.22
Market Capitalization$231.08M
P/E Ratio (Annual)160.47x
All Metrics
Book Value / Share (Quarterly)$1.51
P/TBV (Annual)4.33x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.34
Price vs S&P 500 (YTD)15.23%
EPS (TTM)$-29.10
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-29.10
EPS (Annual)$0.19
ROI (Annual)-623.87%
Net Profit Margin (5Y Avg)-491.62%
Cash / Share (Quarterly)$1.78
P/E Normalized (Annual)160.47x
ROA (Last FY)3.88%
EBITD / Share (TTM)$-1.59
ROE (5Y Avg)-191.87%
Cash Flow / Share (Annual)$-0.31
P/B Ratio28.89x
P/B Ratio (Quarterly)4.28x
Net Income / Employee (Annual)$205,700
Net Interest Coverage (TTM)-2584.50x
ROA (TTM)-662.77%
EV / EBITDA (TTM)38.98x
EPS Incl Extra (Annual)$0.19
Current Ratio (Annual)36.28x
Quick Ratio (Quarterly)17.44x
3-Month Avg Trading Volume0.21M
52-Week Price Return177.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.49
P/S Ratio (Annual)5.61x
Asset Turnover (Annual)0.71x
52-Week High$12.46
Operating Margin (5Y Avg)-476.85%
EPS Excl Extra (Annual)$0.19
Tangible BV CAGR (5Y)-35.67%
26-Week Price Return18.66%
Quick Ratio (Annual)35.98x
13-Week Price Return-16.50%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)17.65x
Enterprise Value$258.42M
Book Value / Share Growth (5Y)-42.53%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)4.71%
Cash / Share (Annual)$1.90
3-Month Return Std Dev104.33%
Net Income / Employee (TTM)$-59,296,400
ROE (Last FY)-623.87%
Net Interest Coverage (Annual)-432.67x
EPS Basic Excl Extra (Annual)$0.19
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-29.10
ROI (TTM)-169.62%
Pretax Margin (5Y Avg)-501.48%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.49
Price vs S&P 500 (52W)152.73%
Year-to-Date Return23.38%
5-Day Price Return2.48%
EPS Normalized (Annual)$0.19
ROA (5Y Avg)-33.70%
Net Profit Margin (Annual)4.71%
Month-to-Date Return1.02%
Cash Flow / Share (TTM)$-3.53
EBITD / Share (Annual)$-2.91
Operating Margin (Annual)4.49%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-191.73%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-29.10
P/TBV (Quarterly)4.33x
P/B Ratio (Annual)4.28x
Book Value / Share (Annual)$1.51
Price vs S&P 500 (13W)-24.75%
Beta-0.04x
P/FCF (Annual)76.01x
Revenue / Share (TTM)$0.00
ROE (TTM)-169.62%
52-Week Low$1.57
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.17est. -0.13
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.29
2.29
2.29
3.89
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NERVMinerva Neurosciences, Inc | — | — | B | $4.96 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. Its pipeline includes Roluperidone for schizophrenia negative symptoms, Seltorexant for insomnia and depression, and MIN-301 for Parkinson's disease.